Research and Development Leadership Team

Born: 1972

Employed since: 2012

Other assignments: –

Education: Ph.D. in Physiology, Stockholm University; Licentiate degree in physiology, Stockholm University; Master’s degree in biology, Stock-holm University, Sweden.

Experience and prior assignments:Over 20 years of experience in drug development in executive positions in R&D, and development in the global pharma and biotech industry.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 27 355 Class B shares. Warrants granting acquisition rights to 8000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1962

Employed since: 2019

Other assignments: –

Education: PhD biochemistry at Linköping University

Experience and prior assignments: Over 25 years of experience in drug development for various disease areas with a focus on neurodegenerative diseases. Leading positions within preclinical research at Roche, AstraZeneca, Nuevolution, Maxygen and Novo Nordisk A/S. PostDoc position at the California Institute of Technology (Caltech).

Member of BioArctic’s R&D Leadership team since: 2023

Total holdings* och warrants i BioArctic: 0 shares. Warrants granting acquisition rights to 30 000 Class B-shares (program 2019/2028).

*Includes holdings by self, closely associated persons, controlled companies or in capital insurance accounts.

Born: 1949

Employed since: 2016

Other assignments: Board member of BioArctic AB, Demban AB and LPB Sweden AB.

Education: Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.

Experience and prior assignments: More than 35 years of experience in research into Alzheimer’s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University; member of the Royal Swedish Academy of Sciences. Founder of BioArctic in 2003, Chairman of the Board and a number of assignments and roles in the company.

Member of BioArctic’s senior management since: 2003

Total holdings* and warrants in BioArctic: 8,639,998 Class A shares through Demban AB. 22,635,052 Class B shares through Demban AB.

Born: 1967

Employed since: 2012

Other assignments –

Education: Master of Chemical Engineering, KTH Royal Institute of Technology; Ph.D. in organic chemistry, KTH; Stockholm, Sweden.

Experience and prior assignments: Over 20 years of experience in drug development and 20 years of experience as R&D director in process development and GMP manufacturing. Former section manager in Process R&D at AstraZeneca.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 12, 470 shares Warrants granting acquisition rights to 14,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1959

Employed at the company since: 2006.

Other assignments –

Education: B.Sc. in Biology, Stockholm University, Sweden; Ph.D. in Medical Science, Karolinska Institutet, Stockholm, Sweden.

Experience and prior assignments: Over 20 years of experience in developing protein drugs from idea to clinical trials including leading positions at small biotech/pharma companies such as Zymenex A/S. In addition, comprehensive academic experience from research projects concerning growth factors and preclinical research in diabetes.

Member of BioArctic’s senior management since: 2006

Total holdings* and warrants in BioArctic: 55, 770 Class B shares.
Warrants granting acquisition rights to 18,000 Class B shares (2019/2028 program)

Born: 1959

Employed since: 2019 (contracted since 2016)

Other assignment: Senior Clinical Consultant at GKeller Consulting

Education: MD Uppsala University, PhD Karolinska Institute, Neurologist certified by the Swedish Medical Society, Diploma in Pharmaceutical Medicine EUCOR/ECPM.

Experience and prior assignments: Over 25 years of experience in the pharma industry, in leading positions in clinical research at AstraZeneca and H. Lundbeck. Chief Specialist ICR Neurology H Lundbeck A/S (2015–2017).

Member of BioArctic’s senior management since: 2020

Total holdings* and warrants in BioArctic: 5,700 Class B-shares. Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1961

Employed since: 2013

Other assignments: Board member of Egetis Therapeutics AB.

Education: Pharmacist; Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden.

Experience and prior assignments: More than 35 years of experience in drug development. Executive positions at Astra/AstraZeneca, including Vice President responsible for the product portfolio in neurodegenerative diseases. Board member of SP Process Development AB.

Member of BioArctic’s senior management since: 2013

Total holdings* and warrants in BioArctic: 84,800 Class B shares. Warrants granting acquisition rights to 90,000 Class B shares (2019/2028 program). 10,000 performance-based share units (2023/2026 program).